Glutamatergic transmission is widely implicated in neuropsychiatric disorders, and the discovery that ketamine elicits rapid-acting antidepressant effects by modulating α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) signaling has spurred a resurgence of interest in the field. This review explores agents in various stages of development for neuropsychiatric disorders that positively modulate AMPARs, both directly and indirectly. Despite promising preclinical research, few direct and indirect AMPAR positive modulators have progressed past early clinical development. Challenges such as low potency have created barriers to effective implementation. Nevertheless, the functional complexity of AMPARs sets them apart from other drug targets and allows for specificity in drug discovery. Additional effective treatments for neuropsychiatric disorders that work through positive AMPAR modulation may eventually be developed.
Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road / B. Kadriu, L. Musazzi, J.N. Johnston, L.E. Kalynchuk, H.J. Caruncho, M. Popoli, C.A. Zarate. - In: DRUG DISCOVERY TODAY. - ISSN 1359-6446. - (2021 Aug 03). [Epub ahead of print] [10.1016/j.drudis.2021.07.027]
Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road
L. MusazziSecondo
;M. PopoliPenultimo
;
2021
Abstract
Glutamatergic transmission is widely implicated in neuropsychiatric disorders, and the discovery that ketamine elicits rapid-acting antidepressant effects by modulating α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) signaling has spurred a resurgence of interest in the field. This review explores agents in various stages of development for neuropsychiatric disorders that positively modulate AMPARs, both directly and indirectly. Despite promising preclinical research, few direct and indirect AMPAR positive modulators have progressed past early clinical development. Challenges such as low potency have created barriers to effective implementation. Nevertheless, the functional complexity of AMPARs sets them apart from other drug targets and allows for specificity in drug discovery. Additional effective treatments for neuropsychiatric disorders that work through positive AMPAR modulation may eventually be developed.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1359644621003536-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
448.39 kB
Formato
Adobe PDF
|
448.39 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.